Peptides for gut health and digestion
Your gut lining replaces itself every few days, and a lot can interfere — stress, medications, inflammation. This topic collects articles on how digestive tissue heals and where peptides for gut health fit into that research, especially BPC-157, which is based on a protective protein found in stomach juice.
Expect plain explanations of mechanisms and honest readings of the evidence, most of it preclinical. Anything offered through Promise is prescription-only: a licensed provider decides whether it's appropriate for you.
17 articles on this topic
-
Does Tirzepatide Cause Acid Reflux? It Can
Tirzepatide can cause reflux and indigestion. The brand labels show how often each was reported, while persistent or severe symptoms need a clinician's review.
-
Should I Take BPC-157? How a Provider Decides
Should I take BPC-157? It may be worth discussing for a specific, examined problem, but a provider first checks the injury, the gut, drug testing, cancer history, pregnancy and your other medicines.
-
Semaglutide Diarrhea: How Common and How Long
Diarrhea is one of semaglutide's most common side effects, especially while the dose is still climbing. Most episodes in the trials lasted about three days; the ones that keep going are the ones to report.
-
Does Semaglutide Cause Acid Reflux? Sometimes
Heartburn and indigestion are listed semaglutide side effects, more common than on placebo but far less common than nausea. Here is how often they show up, why, when they peak, and which signs need a doctor.
-
KPV FDA Review: What the July Vote Really Changed
KPV has never been approved as a U.S. drug. A July 2026 advisory vote favored possible 503A listing, but it did not change the list or approve a product.
-
BPC-157 and Alcohol: Can You Drink Safely?
No published human study has tested the combination. The alcohol claims come from experiments in mice and rats, which cannot establish a safe drinking amount or a hangover remedy.
-
Who Discovered BPC-157? Predrag Sikirić
Predrag Sikirić's group at the University of Zagreb described the parent gastric peptide in 1992 and the 15-amino-acid fragment BPC-157 in 1993. The history is much clearer than the human evidence.
-
KPV Peptide Benefits: What the Evidence Shows
KPV's strongest benefit signals are lower inflammatory activity in cultured cells and mouse colitis models. No human trial has established a KPV benefit, dose, or safety profile.
-
BPC-157 Benefits: What the Evidence Actually Shows
BPC-157 has been studied across connective tissue, gut, inflammatory, nerve, and vascular models. The catch is decisive: most findings come from animals or cells, not controlled human trials.
-
Semaglutide Sulfur Burps: Why They Happen
Sulfur-smelling burps are a real but poorly measured digestive complaint with semaglutide. Trials counted belching, not its smell, and the likely explanation combines slower digestion with hydrogen-sulfide gas.
-
BPC-157 for Inflammation: What the Evidence Shows
Rodent studies report smaller gut lesions, lower oxidative-stress measures and altered inflammatory signaling. No human trial has established dependable anti-inflammatory efficacy for BPC-157.
-
KLOW vs GLOW: What KPV Adds to the Blend
KLOW and GLOW share BPC-157, TB-500, and GHK-Cu; KLOW adds KPV, an inflammation-focused tripeptide backed by cell and mouse studies—not blend-level human trials.
-
Tirzepatide Constipation: How Long It Lasts
Tirzepatide constipation is common, especially in the first weeks and after dose increases. It often eases as treatment stabilizes, while severe or persistent symptoms need a clinician’s attention.
-
Semaglutide Constipation: What Helps
Semaglutide constipation is common during initiation and dose escalation. It usually eases, but it can last longer than other stomach side effects and deserves a clear plan with the prescriber.
-
Oral BPC-157: Do Capsules Work?
Oral activity has been reported in rat gut models, but capsules have not been tested in human trials and their absorption in people has not been measured. A capsule label cannot close that evidence gap.
-
Tirzepatide Diarrhea: How Long It Lasts
Diarrhea is common with tirzepatide, especially after treatment begins or the dose increases. It is usually temporary, but persistent symptoms can cause dehydration and deserve a clinician's attention.
-
KPV Peptide and the Gut Inflammation Evidence
KPV is the C-terminal tripeptide of alpha-MSH, and in mice whose MC1R does not function, every animal in the KPV-treated group survived DSS colitis — a result that points away from melanocortin receptors entirely.